Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.79
Bid: 93.35
Ask: 93.36
Change: 0.00 (0.00%)
Spread: 0.01 (0.011%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 90.79
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Winter is coming... and so are earnings downgrades

Wed, 07th Dec 2022 11:43

STOXX 600 falls 0.5%

*

U.S. banks warn of recession

*

GSK surges after Zantac lawsuits dismissed

*

U.S. stock futures slip

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

WINTER IS COMING... AND SO ARE EARNINGS DOWNGRADES (1143 GMT)

Downgrades to European earnings estimates are picking up, as the regional economy buckles under the weight of red-hot inflation and tighter credit conditions. BofA Global Research's quant team said their three-month European EPS revision ratio fell deeper into what they called "downgrade territory" to 0.82 from 0.99.

The three European stocks with the most negative breadth of EPS revisions were German chemicals maker Covestro, Dutch paints and coatings manufacturer Akzo Nobel and German sportswear company Adidas, the team, led by Paulina Strzelinska, said. The three with the most positive breadth of revisions were Dublin-based aviation leasing company Aercap, Swedish lender SEB and Spanish bank BBVA.

Europe-focused equity funds have recorded a record-breaking 42nd consecutive week of outflows this year ($0.88bn), with a net -21.8% seeing net inflows, the bank said.

BEING BEARISH BUT ALSO BULLISH ON EUROPE INC (1116 GMT)

Jefferies goes straight to point to highlight how different each European country equity market is, which in turns means the dispersion of returns in the region is going to vary widely.

"One size doesn't fit all," says Sean Darby, one of the bank's global equity strategists.

Darby and team in fact are bullish on countries like France and the UK, modestly bullish on Germany, while at the same time, they're bearish on Poland and modestly so for Italy.

"European bourses are far from homogenous, so the dispersion of equity returns in 2023 will be quite wide," they say.

Bringing all together though, they see gains for the Euro STOXX betting that lead indicators will bottom out in the first half of 2023, followed by earnings revisions with a 3-month lag.

"There is room for the index to climb by ~12% as interest rates are likely to peak in 1Q23. This would leave the index trading on 480," they write.

EUROPEANS JUST LOVE GOOGLE (1039 GMT)

Growth stocks have been all the rage over the past few years, at least until late 2020, when it became apparent that the world economy was recovering and inflation was - at least at that point - ticking up at a comfortable pace. But once rates started rising and inflation began to rip higher, value stocks, which are more closely linked to the underlying economy, reemerged as a top pick. This year, European value stocks, which include the likes of energy, natural resources and autos, have gained 1.7%, compared with a drop of nearly 14% in growth stocks and an 11% fall in the broader STOXX.

In terms of what would-be European investors are interested in, the answer is clear, according to data from retail investing company CMC Markets. "Google" is the most searched-for growth stock in the region, topping the charts in 27 countries, with Meta's "Facebook" a close second, coming out on top in 20 countries. The number of searches varies depending on the population. Germany is the country with the highest number of searches a month and "Google" is the most popular, with 149,000 searches. The Netherlands is second, with 115,000 searches. Ukraine is the country with the most searches for "Facebook", with 107,000 searches a month, followed by the UK and France, with 87,000 and 86,000 searches, respectively.

"Google and Facebook are dominating as the most popular growth stocks across Europe. Both of these companies have a huge influence on the market, and the media, which is why many Europeans are looking to invest in them," Michael Hewson, chief market analyst at CMC Markets said.

FORZA ITALIA IN EARLY EUROPE (0915 GMT)

Italy may not have made it to the soccer World Cup, but Milan blue-chips are leading the way this morning, as European equities trade in a sea of red so far. The FTSE MIB is up 0.6%, by far the best performing index in the region, compared with a 0.1% loss in the broader STOXX 600 index, and well beyond Stockholm's 0.5% loss. Utility company ENEL is leading its sector higher and is up 1.5%, making it one of the biggest positive weights on the STOXX and lender UniCredit is up 1.8%.

But today belongs to the pharma and biotech sector, which is the standout gainer, up 1% thanks to a surge in shares of UK drugmaker GSK following a U.S. ruling that dismissed thousands of lawsuits claiming that over-the-counter heartburn medication Zantac causes cancer. The stock rose as much as 15% earlier on and, with a 10% gain, is on track for its largest one-day rise since 1998. French rival Sanofi, which is also part of the suit, is up 5.7%. All the drugmakers involved denied Zantac caused cancer.

HAT-TRICK (0755 GMT)

While European shares ended lower for the third straight session on Tuesday, spooked by recession worries, another hat-trick dominated the World Cup a few hours later.

Three goals by Portugal's 21-year-old Goncalo Ramos against Spain in his first World Cup sent his side through to the quarter-finals for the first time in 16 years. And a 3-0 shootout win by Morocco against former champions Spain meant that Morocco became the first Arab nation ever to qualify for the tournament's quarter-finals.

In the arena of European stocks, there seem to be little excitement for risky assets on Wednesday, with Asian equities trading rangebound after U.S. stocks again suffered losses as markets gradually factor in sharper interest rates hikes.

For the euro zone, commentary by officials is hinting at a peak in rates but anaemic growth and stubbornly high inflation are haunting investors.

ECB policymaker Constantinos Herodotou said on Tuesday that interest rates will go up again but are now "very near" their neutral level.

Markets will focus on industrial output data due from Germany, while euro zone third-quarter GDP and employment numbers, and UK house prices are among the other economic indicators for the day.

Euro zone government bond yields dropped for the first time in three days on Tuesday in the run-up to a raft of major central bank decisions next week.

A Reuters poll of market strategists expect the dollar to rebound against most currencies over the coming months, with the growing threat of recession in the U.S. and elsewhere keeping it firm in 2023 through safe-haven flows.

On Tuesday, top bankers from JPMorgan Chase & Co, Bank of America and Goldman Sachs warned of a recession next year, as inflation threatens consumer demand.

On the corporate front, Airbus gave up a numerical forecast for jet deliveries and a date for its key production goal but retained its financial targets as it limped towards the end of a year battered by disruptions in factories and supply chains.

And British Prime Minister Rishi Sunak's government said it would ease restrictions on building onshore wind farms, heading off a revolt by his party's lawmakers who had demanded they should be permitted with local support.

Key developments that could influence markets on Wednesday:

Economic data: Germany Oct industrial production, Euro zone Q3 GDP, employment (final), UK Nov Halifax house prices

Speakers: ECB's Philip Lane, Elizabeth McCaul and Fabio Panetta

More News
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and dairy workers, veterinarians and lab technicians, government officials said, moves influenza experts say could curb the threat of a pandemic.

Read more
23 May 2024 19:21

Zantac not a cause of woman’s cancer, jury says in first trial over drug

CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar allegations.

Read more
22 May 2024 22:59

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 22 (Reuters) -

Read more
10 May 2024 17:21

STOXX 600 closes at record high on earnings, rate cut optimism

Rio Tinto considered bid for BHP-target Anglo American -report

*

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.